Trial Profile
A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily dose of 2g in Haemodialysis Patients with Moderate to Severe Uremic Pruritus
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Diroleuton (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Sponsors DS Biopharma
- 30 Jul 2022 This trial has been discontinued in Estonia (Date of the global end of the trial : 22-May-2022), according to European Clinical Trials Database record.
- 20 Sep 2018 This trial has been Discontinued in Latvia , according to European Clinical Trials Database
- 08 Feb 2018 New trial record